Clinical Edge Journal Scan

Perceived distress linked to inflammatory arthritis among at-risk individuals


 

Key clinical point: Higher perceived distress was associated with elevated risk of developing inflammatory arthritis (IA) in an at-risk population having either positive rheumatoid arthritis (RA)-related autoantibodies or inherent genetic risk based on family history.

Major finding: A 1-point increase in the perceived distress score was significantly associated with a 10% increase in the risk of incident IA (adjusted hazard ratio [aHR], 1.10; 95% confidence interval [CI], 1.02-1.19). Total perceived stress (aHR, 1.05; 95% CI, 0.99-1.10) and self-efficacy (aHR, 1.04; 95% CI, 0.91-1.18) scores were not significantly associated with the risk of incident IA.

Study details: This prospective cohort study evaluated 448 participants at an increased risk of developing future RA (either first-degree relatives of RA probands or positive for anti-citrullinated protein antibodies) from the Studies of the Etiologies of Rheumatoid Arthritis cohort.

Disclosures: The study was supported by grants from the National Institutes of Health. The authors declared no conflicts of interest.

Source: Polinski KJ et al. Arthritis Care Res (Hoboken). 2020 Nov 6. doi: 10.1002/acr.24085 .

Recommended Reading

TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible
MDedge Rheumatology
Advent of biologics extended life expectancy but also expenses for RA patients
MDedge Rheumatology
Baricitinib combo for COVID-19 accelerates recovery, study shows
MDedge Rheumatology
Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients
MDedge Rheumatology
Gut microbiome influences response to methotrexate in new-onset RA patients
MDedge Rheumatology
"Lipid paradox” seen in nonobese RA patients with low LDL
MDedge Rheumatology
EULAR recommendations define strategies to improve adherence in RMDs
MDedge Rheumatology
Early treatment response may predict sustained DMARD-free remission in RA
MDedge Rheumatology
Baricitinib favorable for long-term treatment of moderate to severe RA
MDedge Rheumatology
ANA measurement before TNFi therapy could help predict treatment failure in RA
MDedge Rheumatology